BiotechTube
Integro Theranostics

Integro Theranostics

Philadelphia, United States· Est.
integrotheranostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Integro Theranostics is pioneering a targeted fluorescence imaging platform designed to make cancer cells visible during surgery, thereby enabling more complete tumor resections and reducing recurrence rates. Founded in 2019 and based in Philadelphia, the company is advancing its lead agent, CXL (formerly LS301), through clinical development alongside its proprietary CancerVision® Goggles and AI-powered data analytics tools. By focusing on real-time, intraoperative visualization, Integro aims to directly improve patient outcomes while also building a data ecosystem to optimize clinical trials. The company emphasizes a commitment to health equity, seeking to improve access and representation in oncology care and research.

Oncology

Technology Platform

Intraoperative Molecular Imaging (IMI) platform combining a targeted fluorescent peptide-dye conjugate (CXL) that binds to activated proteins on cancer cells, proprietary wearable near-infrared goggles (CancerVision®), and AI/ML software for data analysis and surgical guidance.

Opportunities

The platform addresses a major unmet need in surgical oncology by enabling real-time visualization of cancer margins, which can reduce recurrence rates and repeat surgeries.
The integration of AI for data analysis creates an additional revenue stream in clinical trial optimization and surgical decision support.
A focus on health equity can facilitate partnerships, grants, and broader market access in underserved populations.

Risk Factors

The company faces significant clinical and regulatory risk in proving efficacy and safety for its novel drug-device combination.
Market adoption and securing reimbursement from payers for both the imaging agent and the procedure are major commercialization hurdles.
It operates in a competitive and capital-intensive space, with dependence on fundraising to reach key milestones.

Competitive Landscape

Integro competes in the growing intraoperative imaging market against companies like On Target Laboratories (FDA-approved Cytalux) and other developers of targeted fluorescent agents. It also faces competition from larger medtech companies offering broad surgical visualization/navigation systems. Differentiation hinges on CXL's specific target profile, dosing flexibility, and the integrated AI/goggle ecosystem.

More companies in Diagnostics & Precision Medicine →More companies in United States →